Jianxiong Wu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jianxiong Wu has a total of 170 co-authors. Here are the top co-authors by number of shared publications:
Fan Wu
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
11 shared publicationsChangcheng Tao
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
10 shared publicationsKai Zhang
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
9 shared publications- Weiqi Rong
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
9 shared publications Liming Wang
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People’s Republic of China
7 shared publicationsYue Liu
Department of Hepatobiliary Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
6 shared publications
Latest Publications
- Open Access
- 6 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, and liver metastases stands as a leading contributor to its high mortality rate in advanced stages. Regorafenib plus anti-PD-1 is a new therapeutic option for patients with colorectal cancer liver metastases (CRCLM). However, a considerable number of patients have not benefited from it. In this study, KRAS mutation was identified associated with resistance to regorafenib plus anti-PD-1 in CRCLM. Dihydroartemisinin (DHA), a clinically approved anti-malaria agent, was verified to selectively downregulate KRAS G12D mutant with no discernible influences on wild-type KRAS, which is consistent with the higher sensitivity of KRAS -mutant CRC cells and organoids to DHA treatment. In preclinical KRAS G12D CRCLM models, DHA substantially potentiated the therapeutic efficacy of regorafenib plus anti-PD-1 by remodeling the tumor immune microenvironment, including enhancing the cytotoxicity of CD8 + effector T cells and promoting pro-inflammatory macrophage polarization. Mechanically, DHA could restore interferon response that was impaired by oncogenic KRAS mutations, and inhibit ERBB signaling activation induced by regorafenib. Collectively, these findings support DHA as a potential adjunct to regorafenib plus anti-PD-1 for KRAS G12D CRCLM and suggest a therapeutic strategy with translational potential for KRAS -driven malignancies.
- 6 July 2026
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Open AccessDihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases
Colorectal cancer (CRC) is one of the most prevalent malignancies worldwide, and liver metastases stands as a leading contributor to its high mortality rate in advanced stages. Regorafenib plus anti-PD-1 is a new therapeutic option for patients with colorectal cancer liver metastases (CRCLM). However, a considerable number of patients have not benefited from it. In this study, KRAS mutation was identified associated with resistance to regorafenib plus anti-PD-1 in CRCLM. Dihydroartemisinin (DHA), a clinically approved anti-malaria agent, was verified to selectively downregulate KRAS G12D mutant with no discernible influences on wild-type KRAS, which is consistent with the higher sensitivity of KRAS -mutant CRC cells and organoids to DHA treatment. In preclinical KRAS G12D CRCLM models, DHA substantially potentiated the therapeutic efficacy of regorafenib plus anti-PD-1 by remodeling the tumor immune microenvironment, including enhancing the cytotoxicity of CD8 + effector T cells and promoting pro-inflammatory macrophage polarization. Mechanically, DHA could restore interferon response that was impaired by oncogenic KRAS mutations, and inhibit ERBB signaling activation induced by regorafenib. Collectively, these findings support DHA as a potential adjunct to regorafenib plus anti-PD-1 for KRAS G12D CRCLM and suggest a therapeutic strategy with translational potential for KRAS -driven malignancies.
- Open Access
- 23 February 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (2) , 272
Occupational Hazards, Social Support, and Quality of Working Life in Sub-District Health Promoting Hospitals in Southern Thailand: A Cross-Sectional Study
Healthcare personnel working in sub-district health promoting hospitals (SHPHs) are vital to Thailand’s primary healthcare system but often face occupational, psychosocial, and organizational challenges that may affect their quality of working life (QWL). This study aimed to assess QWL and identify its key predictors among SHPH healthcare personnel in southern Thailand. A cross-sectional survey was conducted among 340 healthcare personnel in Nakhon Si Thammarat Province using stratified random sampling. Data were collected through a structured questionnaire covering socio-demographic characteristics, working conditions, occupational hazard exposures, social support, and QWL measured by the 36-item Thai version of the QWL scale. Descriptive statistics and stepwise multiple linear regression analyses were performed. Participants were predominantly female (80.9%) with a mean age of 34.0 years (SD = 9.2), and one-third (33.2%) worked more than eight hours per day. Most participants (75.6%) had moderate hazard exposure, while 73.2% reported high social support. Overall, 51.2% of respondents had good QWL, with safe and healthy working conditions and social relevance of work life rated highest. Regression analysis identified social support (β = 0.790, p < 0.001) and working hours per day (β = 0.109, p = 0.001) as positive predictors, while work experience (β = −0.064, p = 0.049) was a negative predictor (R2 = 0.655). These findings emphasize the need for organizational strategies that strengthen social support and effectively manage working conditions, including the organization of working hours, to promote sustainable quality of working life among healthcare personnel in Thailand’s primary healthcare system.
- 23 February 2026
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 23 (2) , 272
Open AccessOccupational Hazards, Social Support, and Quality of Working Life in Sub-District Health Promoting Hospitals in Southern Thailand: A Cross-Sectional Study
Healthcare personnel working in sub-district health promoting hospitals (SHPHs) are vital to Thailand’s primary healthcare system but often face occupational, psychosocial, and organizational challenges that may affect their quality of working life (QWL). This study aimed to assess QWL and identify its key predictors among SHPH healthcare personnel in southern Thailand. A cross-sectional survey was conducted among 340 healthcare personnel in Nakhon Si Thammarat Province using stratified random sampling. Data were collected through a structured questionnaire covering socio-demographic characteristics, working conditions, occupational hazard exposures, social support, and QWL measured by the 36-item Thai version of the QWL scale. Descriptive statistics and stepwise multiple linear regression analyses were performed. Participants were predominantly female (80.9%) with a mean age of 34.0 years (SD = 9.2), and one-third (33.2%) worked more than eight hours per day. Most participants (75.6%) had moderate hazard exposure, while 73.2% reported high social support. Overall, 51.2% of respondents had good QWL, with safe and healthy working conditions and social relevance of work life rated highest. Regression analysis identified social support (β = 0.790, p < 0.001) and working hours per day (β = 0.109, p = 0.001) as positive predictors, while work experience (β = −0.064, p = 0.049) was a negative predictor (R2 = 0.655). These findings emphasize the need for organizational strategies that strengthen social support and effectively manage working conditions, including the organization of working hours, to promote sustainable quality of working life among healthcare personnel in Thailand’s primary healthcare system.
- Open Access
- 21 February 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 32 (7) , 113973
Lactate metabolism-driven tumor heterogeneity and molecular signatures in intrahepatic cholangiocarcinoma
BACKGROUND Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive liver malignancy with limited therapeutic options and poor prognosis. Recent evidence indicates that lactate metabolism (LM) plays a pivotal role in tumor metabolic reprogramming, immune evasion, and disease progression; however, the heterogeneity and regulatory mechanisms of LM activity within ICC remain largely undefined. AIM To systematically characterize LM-driven heterogeneity and its molecular and functional implications in ICC. METHODS Single-cell RNA sequencing and bulk transcriptomic datasets were integrated to characterize LM heterogeneity in ICC. High-dimensional weighted gene co-expression network analysis and multiple machine-learning algorithms (least absolute shrinkage and selection operator, random forest, gradient boosting machine, adaptive best subset selection, and decision tree) were employed to identify LM-associated feature genes. CytoTRACE and CellChat analyses were used to assess differentiation potential and intercellular communication among malignant epithelial subpopulations. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were performed to elucidate biological functions. A random forest model combined with SHapley Additive exPlanation (SHAP) interpretability analysis identified the most predictive LM-related gene. Functional assays, including quantitative polymerase chain reaction, cell counting kit-8, colony formation, wound-healing, and transwell experiments, were conducted to validate CYC1 in ICC cell lines. RESULTS Malignant ICC cells were stratified into three LM-activity subtypes (high, intermediate, and low) exhibiting distinct transcriptional programs and differentiation trajectories. Twelve LM-associated feature genes GPX3 , CYC1 , NME1 , GSTP1 , MGST1 , ALDH3A1 , TALDO1 , SNRPB , TKT , NAA20 , G6PD , and RPL13A were identified as key molecular markers linked to aggressive phenotypes and poor prognosis. Among them, CYC1 showed the highest predictive accuracy (area under the curve = 0.844) and strongest model contribution (SHAP = 0.091), marking it as the principal LM-related driver gene. Functional experiments confirmed that CYC1 knockdown significantly suppressed ICC cell proliferation, migration, and invasion, validating its oncogenic role in promoting malignant progression. CONCLUSION This integrative single-cell and machine-learning study delineates the molecular heterogeneity of LM in ICC and identifies twelve feature genes linking LM with tumor aggressiveness. These findings provide novel insight into LM-driven oncogenic mechanisms and propose CYC1 and other LM-associated genes as potential biomarkers and therapeutic targets for ICC.
- 21 February 2026
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 32 (7) , 113973
Open AccessLactate metabolism-driven tumor heterogeneity and molecular signatures in intrahepatic cholangiocarcinoma
BACKGROUND Intrahepatic cholangiocarcinoma (ICC) is a highly aggressive liver malignancy with limited therapeutic options and poor prognosis. Recent evidence indicates that lactate metabolism (LM) plays a pivotal role in tumor metabolic reprogramming, immune evasion, and disease progression; however, the heterogeneity and regulatory mechanisms of LM activity within ICC remain largely undefined. AIM To systematically characterize LM-driven heterogeneity and its molecular and functional implications in ICC. METHODS Single-cell RNA sequencing and bulk transcriptomic datasets were integrated to characterize LM heterogeneity in ICC. High-dimensional weighted gene co-expression network analysis and multiple machine-learning algorithms (least absolute shrinkage and selection operator, random forest, gradient boosting machine, adaptive best subset selection, and decision tree) were employed to identify LM-associated feature genes. CytoTRACE and CellChat analyses were used to assess differentiation potential and intercellular communication among malignant epithelial subpopulations. Kyoto Encyclopedia of Genes and Genomes and Gene Ontology enrichment analyses were performed to elucidate biological functions. A random forest model combined with SHapley Additive exPlanation (SHAP) interpretability analysis identified the most predictive LM-related gene. Functional assays, including quantitative polymerase chain reaction, cell counting kit-8, colony formation, wound-healing, and transwell experiments, were conducted to validate CYC1 in ICC cell lines. RESULTS Malignant ICC cells were stratified into three LM-activity subtypes (high, intermediate, and low) exhibiting distinct transcriptional programs and differentiation trajectories. Twelve LM-associated feature genes GPX3 , CYC1 , NME1 , GSTP1 , MGST1 , ALDH3A1 , TALDO1 , SNRPB , TKT , NAA20 , G6PD , and RPL13A were identified as key molecular markers linked to aggressive phenotypes and poor prognosis. Among them, CYC1 showed the highest predictive accuracy (area under the curve = 0.844) and strongest model contribution (SHAP = 0.091), marking it as the principal LM-related driver gene. Functional experiments confirmed that CYC1 knockdown significantly suppressed ICC cell proliferation, migration, and invasion, validating its oncogenic role in promoting malignant progression. CONCLUSION This integrative single-cell and machine-learning study delineates the molecular heterogeneity of LM in ICC and identifies twelve feature genes linking LM with tumor aggressiveness. These findings provide novel insight into LM-driven oncogenic mechanisms and propose CYC1 and other LM-associated genes as potential biomarkers and therapeutic targets for ICC.
- Top Cited PapersOpen Access
- 26 December 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
A novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains
Large language models (LLMs) hold promise in clinical decision support but face major challenges in safety evaluation and effectiveness validation. We developed the Clinical Safety-Effectiveness Dual-Track Benchmark (CSEDB), a multidimensional framework built on clinical expert consensus, encompassing 30 metrics covering critical areas like critical illness recognition, guideline adherence, and medication safety, with weighted consequence measures. Thirty-two specialist physicians developed and revised 2069 open-ended Q&A items aligned with these criteria, spanning 26 clinical departments to simulate real-world scenarios. Benchmark testing of six LLMs revealed moderate overall performance (average total score 57.2%, safety 54.7%, effectiveness 62.3%), with a significant 13.3% performance drop in high-risk scenarios ( p < 0.0001). Domain-specific medical LLMs showed consistent performance advantages over general-purpose models, with relatively higher top scores in safety (0.912) and effectiveness (0.861). The findings of this study not only provide a standardized metric for evaluating the clinical application of medical LLMs, facilitating comparative analyses, risk exposure identification, and improvement directions across different scenarios, but also hold the potential to promote safer and more effective deployment of large language models in healthcare environments.
- 26 December 2025
- Published by Springer Nature in npj Digital Medicine
- Vol. 9 (1)
Top Cited PapersOpen AccessA novel evaluation benchmark for medical LLMs illuminating safety and effectiveness in clinical domains
Large language models (LLMs) hold promise in clinical decision support but face major challenges in safety evaluation and effectiveness validation. We developed the Clinical Safety-Effectiveness Dual-Track Benchmark (CSEDB), a multidimensional framework built on clinical expert consensus, encompassing 30 metrics covering critical areas like critical illness recognition, guideline adherence, and medication safety, with weighted consequence measures. Thirty-two specialist physicians developed and revised 2069 open-ended Q&A items aligned with these criteria, spanning 26 clinical departments to simulate real-world scenarios. Benchmark testing of six LLMs revealed moderate overall performance (average total score 57.2%, safety 54.7%, effectiveness 62.3%), with a significant 13.3% performance drop in high-risk scenarios ( p < 0.0001). Domain-specific medical LLMs showed consistent performance advantages over general-purpose models, with relatively higher top scores in safety (0.912) and effectiveness (0.861). The findings of this study not only provide a standardized metric for evaluating the clinical application of medical LLMs, facilitating comparative analyses, risk exposure identification, and improvement directions across different scenarios, but also hold the potential to promote safer and more effective deployment of large language models in healthcare environments.
- Open Access
- 1 February 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 261-274
Effect of Narrow-Margin Hepatectomy Combined with Intraoperative Radiotherapy on Long-Term Prognosis of Patients with Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Background: Radiotherapy offers potential benefits for patients with hepatocellular carcinoma (HCC); however, the distinct role of intraoperative radiotherapy (IORT) during narrow-margin hepatectomy remains inadequately defined. This study aims at assessing the safety and effectiveness of IORT for centrally located HCCs during narrow-margin hepatectomy. Methods: This single-center, retrospective research incorporated 659 patients with centrally located HCCs. After applying exclusion criteria, 607 patients remained and were divided into two groups: IORT integrated with liver resection (IORT+LR, 54 patients) and mere liver resection (LR, 553 patients). Propensity score matching (PSM) was performed to balance baseline characteristics. Post PSM, surgical outcomes, long-term recurrence, survival rates and adverse events were analyzed. Results: A total of 54 patients were successfully matched, without significant differences upon baseline characteristics (standardized mean difference, SMD < 0.15). Post-matching analysis revealed that overall survival (OS) and disease-free survival (DFS) were notably improved in the IORT+LR group (P =0.027 and 0.015, respectively). Multivariate Cox regression identified IORT as an independent prognostic factor for better DFS and OS. Among the 108 patients included after matching, 57 experienced HCC recurrence, 23 in the IORT group and 34 in the LR group, showing a clear difference in recurrence rates (P =0.034). Also, there were no apparent differences in mild/severe complications between IORT and RT groups (96.3% vs 98.2%, P =0.558, respectively). Conclusion: IORT is an effective and well-tolerated therapy for HCC patients. The combination of narrow-margin hepatectomy and IORT enhances patient prognosis, with IORT identified as an independent prognostic factor.
- 1 February 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 261-274
Open AccessEffect of Narrow-Margin Hepatectomy Combined with Intraoperative Radiotherapy on Long-Term Prognosis of Patients with Centrally Located Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Background: Radiotherapy offers potential benefits for patients with hepatocellular carcinoma (HCC); however, the distinct role of intraoperative radiotherapy (IORT) during narrow-margin hepatectomy remains inadequately defined. This study aims at assessing the safety and effectiveness of IORT for centrally located HCCs during narrow-margin hepatectomy. Methods: This single-center, retrospective research incorporated 659 patients with centrally located HCCs. After applying exclusion criteria, 607 patients remained and were divided into two groups: IORT integrated with liver resection (IORT+LR, 54 patients) and mere liver resection (LR, 553 patients). Propensity score matching (PSM) was performed to balance baseline characteristics. Post PSM, surgical outcomes, long-term recurrence, survival rates and adverse events were analyzed. Results: A total of 54 patients were successfully matched, without significant differences upon baseline characteristics (standardized mean difference, SMD < 0.15). Post-matching analysis revealed that overall survival (OS) and disease-free survival (DFS) were notably improved in the IORT+LR group (P =0.027 and 0.015, respectively). Multivariate Cox regression identified IORT as an independent prognostic factor for better DFS and OS. Among the 108 patients included after matching, 57 experienced HCC recurrence, 23 in the IORT group and 34 in the LR group, showing a clear difference in recurrence rates (P =0.034). Also, there were no apparent differences in mild/severe complications between IORT and RT groups (96.3% vs 98.2%, P =0.558, respectively). Conclusion: IORT is an effective and well-tolerated therapy for HCC patients. The combination of narrow-margin hepatectomy and IORT enhances patient prognosis, with IORT identified as an independent prognostic factor.
- Open Access
- 28 November 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (3) , 101287
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
- 28 November 2024
- Published by Elsevier in JHEP Reports
- Vol. 7 (3) , 101287
Open AccessPhase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis
- Open Access
- 1 August 2024
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 1481-1493
Radiotherapy with Targeted Therapy or Immune Checkpoint Inhibitors for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombi
Purpose: This study evaluated the clinical outcomes of patients with hepatocellular carcinoma (HCC) with hepatic vein tumor thrombus (HVTT) and/or inferior vena cava tumor thrombus (IVCTT) receiving radiotherapy (RT) combined with systemic therapies. Patients and Methods: Patients with HCC with HVTT and/or IVCTT who received RT were identified at our institution. The prescription doses were 30– 65 Gy for planning target volume and 40– 65 Gy for the gross tumor volume. Targeted therapy and immune checkpoint inhibitors were used concurrently if patients were at a high risk of or already had distant metastasis. After RT completion, follow-up was performed at 1, 3, 6, and 12 months, and 3 to 6 months thereafter. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and toxicity were recorded. Results: Thirty-four patients were retrospectively enrolled between January 2016 and September 2021. Most patients received concurrent targeted therapy (70.6%) and/or post-RT (79.4%). The in-field ORR and disease control rates were 79.4% and 97.1%, respectively. The OS rates were 77.6% at 1 year and 36.3% at 2 years (median OS, 15.8 months). The median PFS and median in-field PFS were 4.2 months and not reached, respectively. The PFS and in-field PFS rates were 24.6% and 79.2% at 1 year, 19.7% and 72.0% at 2 years, respectively. An alpha-fetoprotein level > 1000 ng/mL was a significant prognostic factor for worse OS (HR, 5.674; 95% CI, 1.588– 20.276; p=0.008); in-field complete/partial response was a significant prognostic factor for better OS (HR, 0.116; 95% CI, 0.027– 0.499; p=0.004). The most common site of first failure was the lungs (13/34 patients, 38.2%), followed by the liver (7/34 patients, 20.6%). No patients developed radiation-induced liver disease or pulmonary embolism during follow-up. Conclusion: Combining RT and systemic therapy was safe and effective in treating patients with HCC with HVTT and IVCTT.
- 1 August 2024
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 11, 1481-1493
Open AccessRadiotherapy with Targeted Therapy or Immune Checkpoint Inhibitors for Hepatocellular Carcinoma with Hepatic Vein and/or Inferior Vena Cava Tumor Thrombi
Purpose: This study evaluated the clinical outcomes of patients with hepatocellular carcinoma (HCC) with hepatic vein tumor thrombus (HVTT) and/or inferior vena cava tumor thrombus (IVCTT) receiving radiotherapy (RT) combined with systemic therapies. Patients and Methods: Patients with HCC with HVTT and/or IVCTT who received RT were identified at our institution. The prescription doses were 30– 65 Gy for planning target volume and 40– 65 Gy for the gross tumor volume. Targeted therapy and immune checkpoint inhibitors were used concurrently if patients were at a high risk of or already had distant metastasis. After RT completion, follow-up was performed at 1, 3, 6, and 12 months, and 3 to 6 months thereafter. The objective response rate (ORR), overall survival (OS), progression-free survival (PFS) and toxicity were recorded. Results: Thirty-four patients were retrospectively enrolled between January 2016 and September 2021. Most patients received concurrent targeted therapy (70.6%) and/or post-RT (79.4%). The in-field ORR and disease control rates were 79.4% and 97.1%, respectively. The OS rates were 77.6% at 1 year and 36.3% at 2 years (median OS, 15.8 months). The median PFS and median in-field PFS were 4.2 months and not reached, respectively. The PFS and in-field PFS rates were 24.6% and 79.2% at 1 year, 19.7% and 72.0% at 2 years, respectively. An alpha-fetoprotein level > 1000 ng/mL was a significant prognostic factor for worse OS (HR, 5.674; 95% CI, 1.588– 20.276; p=0.008); in-field complete/partial response was a significant prognostic factor for better OS (HR, 0.116; 95% CI, 0.027– 0.499; p=0.004). The most common site of first failure was the lungs (13/34 patients, 38.2%), followed by the liver (7/34 patients, 20.6%). No patients developed radiation-induced liver disease or pulmonary embolism during follow-up. Conclusion: Combining RT and systemic therapy was safe and effective in treating patients with HCC with HVTT and IVCTT.
- Open Access
- 12 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Long-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study
Despite that surgical resection is widely regarded as the most effective approach to the treatment of liver cancer, its safety and efficacy upon centrally located hepatocellular carcinoma (HCC) remain unsatisfactory. In consequence, seeking an integrated treatment, like combined with adjuvant radiotherapy, to enhance the prognosis of patients is of critical importance. By recruiting patients undergoing surgical resection for centrally located HCC ranging from June 2015 to 2020, they were divided into liver resection combined with adjuvant radiotherapy (LR + RT) and mere liver resection (LR) groups. The calculation of propensity score and model of Cox proportional hazards regression were utilized. 193 patients were recruited in aggregation, containing 88 ones undergoing LR + RT, while 105 handled with LR. RT was verified to be an independent factor of prognosis for relapse (HR 0.60). In propensity-score analyses, significant association existed between adjuvant radiotherapy and better disease-free survival (DFS) (Matched, HR 0.60; Adjustment of propensity score, HR 0.60; Inverse probability weighting, HR 0.63). The difference of DFS was apparent within two groups (p value = 0.022), and RT significantly down-regulated early relapse (p value < 0.05) in subgroup analysis. The calculation of E-value revealed robustness of unmeasured confounding. The combination of liver surgical resection with RT is safe and effective towards patients with centrally located HCC, which would notably enhance the prognosis and decrease the early relapse of HCC.
- 12 April 2024
- Published by Springer Nature in Scientific Reports
- Vol. 14 (1) , 1-10
Open AccessLong-term outcome of adjuvant radiotherapy upon postoperative relapse of centrally located hepatocellular carcinoma: a real-world study
Despite that surgical resection is widely regarded as the most effective approach to the treatment of liver cancer, its safety and efficacy upon centrally located hepatocellular carcinoma (HCC) remain unsatisfactory. In consequence, seeking an integrated treatment, like combined with adjuvant radiotherapy, to enhance the prognosis of patients is of critical importance. By recruiting patients undergoing surgical resection for centrally located HCC ranging from June 2015 to 2020, they were divided into liver resection combined with adjuvant radiotherapy (LR + RT) and mere liver resection (LR) groups. The calculation of propensity score and model of Cox proportional hazards regression were utilized. 193 patients were recruited in aggregation, containing 88 ones undergoing LR + RT, while 105 handled with LR. RT was verified to be an independent factor of prognosis for relapse (HR 0.60). In propensity-score analyses, significant association existed between adjuvant radiotherapy and better disease-free survival (DFS) (Matched, HR 0.60; Adjustment of propensity score, HR 0.60; Inverse probability weighting, HR 0.63). The difference of DFS was apparent within two groups (p value = 0.022), and RT significantly down-regulated early relapse (p value < 0.05) in subgroup analysis. The calculation of E-value revealed robustness of unmeasured confounding. The combination of liver surgical resection with RT is safe and effective towards patients with centrally located HCC, which would notably enhance the prognosis and decrease the early relapse of HCC.
- Open Access
HBV integrations reshaping genomic structures promote hepatocellular carcinoma
Objective: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), mostly characterised by HBV integrations, is prevalent worldwide. Previous HBV studies mainly focused on a few hotspot integrations. However, the oncogenic role of the other HBV integrations remains unclear. This study aimed to elucidate HBV integration-induced tumourigenesis further. Design: Here, we illuminated the genomic structures encompassing HBV integrations in 124 HCCs across ages using whole genome sequencing and Nanopore long reads. We classified a repertoire of integration patterns featured by complex genomic rearrangement. We also conducted a clustered regularly interspaced short palindromic repeat (CRISPR)-based gain-of-function genetic screen in mouse hepatocytes. We individually activated each candidate gene in the mouse model to uncover HBV integration-mediated oncogenic aberration that elicits tumourigenesis in mice. Results: These HBV-mediated rearrangements are significantly enriched in a bridge-fusion-bridge pattern and interchromosomal translocations, and frequently led to a wide range of aberrations including driver copy number variations in chr 4q, 5p ( TERT ), 6q, 8p, 16q, 9p ( CDKN2A/B ), 17p ( TP53 ) and 13q ( RB1 ), and particularly, ultra-early amplifications in chr8q. Integrated HBV frequently contains complex structures correlated with the translocation distance. Paired breakpoints within each integration event usually exhibit different microhomology, likely mediated by different DNA repair mechanisms. HBV-mediated rearrangements significantly correlated with young age, higher HBV DNA level and TP53 mutations but were less prevalent in the patients subjected to prior antiviral therapies. Finally, we recapitulated the TONSL and TMEM65 amplification in chr8q led by HBV integration using CRISPR/Cas9 editing and demonstrated their tumourigenic potentials. Conclusion: HBV integrations extensively reshape genomic structures and promote hepatocarcinogenesis (graphical abstract), which may occur early in a patient’s life.
Open AccessHBV integrations reshaping genomic structures promote hepatocellular carcinoma
Objective: Hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC), mostly characterised by HBV integrations, is prevalent worldwide. Previous HBV studies mainly focused on a few hotspot integrations. However, the oncogenic role of the other HBV integrations remains unclear. This study aimed to elucidate HBV integration-induced tumourigenesis further. Design: Here, we illuminated the genomic structures encompassing HBV integrations in 124 HCCs across ages using whole genome sequencing and Nanopore long reads. We classified a repertoire of integration patterns featured by complex genomic rearrangement. We also conducted a clustered regularly interspaced short palindromic repeat (CRISPR)-based gain-of-function genetic screen in mouse hepatocytes. We individually activated each candidate gene in the mouse model to uncover HBV integration-mediated oncogenic aberration that elicits tumourigenesis in mice. Results: These HBV-mediated rearrangements are significantly enriched in a bridge-fusion-bridge pattern and interchromosomal translocations, and frequently led to a wide range of aberrations including driver copy number variations in chr 4q, 5p ( TERT ), 6q, 8p, 16q, 9p ( CDKN2A/B ), 17p ( TP53 ) and 13q ( RB1 ), and particularly, ultra-early amplifications in chr8q. Integrated HBV frequently contains complex structures correlated with the translocation distance. Paired breakpoints within each integration event usually exhibit different microhomology, likely mediated by different DNA repair mechanisms. HBV-mediated rearrangements significantly correlated with young age, higher HBV DNA level and TP53 mutations but were less prevalent in the patients subjected to prior antiviral therapies. Finally, we recapitulated the TONSL and TMEM65 amplification in chr8q led by HBV integration using CRISPR/Cas9 editing and demonstrated their tumourigenic potentials. Conclusion: HBV integrations extensively reshape genomic structures and promote hepatocarcinogenesis (graphical abstract), which may occur early in a patient’s life.
- Open Access
- 16 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (1) , 78-84
Long-term outcome of centrally located hepatocellular carcinoma treated by neoadjuvant radiotherapy and radical resection: a propensity score matched study
Objective: Centrally located hepatocellular carcinoma (HCC) typically presents challenges in surgical intervention and is associated with a bleak prognosis. In order to address this pressing issue, it is imperative to identify a comprehensive treatment approach, such as neoadjuvant radiotherapy (neoRT), that can enhance the prognosis of patients diagnosed with centrally located HCC. Methods: Patients who had surgical resections for HCC between March 2015 and December 2020 were included in the study. Patients were assigned to either the neoRT combined with liver resection (neoRT+LR) group or the liver resection alone (LR) group. The study employed propensity-score analysis and Cox proportional-hazards regression models as research methodologies. Using the Kaplan–Meier method, overall survival (OS) and disease-free survival (DFS) were estimated in patients. Results: During the study, 162 patients were enrolled, with 41 receiving neoRT+LR and 121 receiving LR. The duration of the median follow-up period was 45 months. The 1-year, 3-year, and 5-year OS rates were 95, 70, and 70% for patients in the neoRT+LR group, and 82, 64, and 54% for patients in the LR group, respectively. The 1-year, 3-year, 5-year DFS rates were 71, 53, and 37% for patients in the neoRT+LR group, and 52, 38, and 34% for patients in the LR group, respectively. A successful matching of 37 patients was achieved through propensity-score analysis. OS and DFS after matching analysis was statistically different between the two groups ( P=0.0099, P=0.034, respectively). neoRT was an independent prognostic factor for OS and DFS [hazard ratio (HR)=0.47, 95% CI: 0.24–0.93; HR=0.56, 95% CI: 0.34–0.92, respectively]. According to matching analysis, there were no statistically significant differences observed in terms of baseline characteristics, surgical safety, and complications between the groups. Conclusion: Liver resection and neoRT can be advantageous for patients with centrally located HCC.
- 16 November 2023
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (1) , 78-84
Open AccessLong-term outcome of centrally located hepatocellular carcinoma treated by neoadjuvant radiotherapy and radical resection: a propensity score matched study
Objective: Centrally located hepatocellular carcinoma (HCC) typically presents challenges in surgical intervention and is associated with a bleak prognosis. In order to address this pressing issue, it is imperative to identify a comprehensive treatment approach, such as neoadjuvant radiotherapy (neoRT), that can enhance the prognosis of patients diagnosed with centrally located HCC. Methods: Patients who had surgical resections for HCC between March 2015 and December 2020 were included in the study. Patients were assigned to either the neoRT combined with liver resection (neoRT+LR) group or the liver resection alone (LR) group. The study employed propensity-score analysis and Cox proportional-hazards regression models as research methodologies. Using the Kaplan–Meier method, overall survival (OS) and disease-free survival (DFS) were estimated in patients. Results: During the study, 162 patients were enrolled, with 41 receiving neoRT+LR and 121 receiving LR. The duration of the median follow-up period was 45 months. The 1-year, 3-year, and 5-year OS rates were 95, 70, and 70% for patients in the neoRT+LR group, and 82, 64, and 54% for patients in the LR group, respectively. The 1-year, 3-year, 5-year DFS rates were 71, 53, and 37% for patients in the neoRT+LR group, and 52, 38, and 34% for patients in the LR group, respectively. A successful matching of 37 patients was achieved through propensity-score analysis. OS and DFS after matching analysis was statistically different between the two groups ( P=0.0099, P=0.034, respectively). neoRT was an independent prognostic factor for OS and DFS [hazard ratio (HR)=0.47, 95% CI: 0.24–0.93; HR=0.56, 95% CI: 0.34–0.92, respectively]. According to matching analysis, there were no statistically significant differences observed in terms of baseline characteristics, surgical safety, and complications between the groups. Conclusion: Liver resection and neoRT can be advantageous for patients with centrally located HCC.